Clinical Trials Logo
  1. Home
  2. Carcinoma, Transitional Cell
  3. NCT00109655

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Carcinoma, Transitional Cell Clinical Trial

Official title:
A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure

Clinical Trial Summary

The main purpose of this research study is to evaluate the safety and dosing of CG0070.

Clinical Trial Description

Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00109655
Study type Interventional
Source Cell Genesys
Contact
Status Active, not recruiting
Phase Phase 1
Start date April 2005
Completion date September 2010
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01215877 - Tesetaxel for Previously Treated Patients With Bladder Cancer Phase 2
Completed NCT03219333 - A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer Phase 2
Terminated NCT02450331 - A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection Phase 3
Active, not recruiting NCT03288545 - A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Phase 1/Phase 2
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00077688 - TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Phase 2
Recruiting NCT05874921 - uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Completed NCT03410693 - Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma Phase 2/Phase 3
Completed NCT02451423 - Neoadjuvant Atezolizumab in Localized Bladder Cancer Phase 2
Completed NCT00001381 - A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder Phase 1
Recruiting NCT05318339 - A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma Phase 2
Completed NCT02443324 - A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Phase 1
Completed NCT00722553 - Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Phase 2
Recruiting NCT00146276 - Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Phase 3
Completed NCT02014337 - Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Phase 1
Recruiting NCT01189838 - The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma N/A
Withdrawn NCT00172367 - Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma Phase 2
Completed NCT00191971 - 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen Phase 2
Terminated NCT00127595 - Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract Phase 2
Terminated NCT04039867 - Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer Phase 2